T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale In Company History; The Initial Order Includes Seven T2DX Instruments, Valued At More Than $450,000, With The Potential For Nine Additional Instruments To Be Sold And Deployed
Portfolio Pulse from Happy Mohamed
T2 Biosystems announces its second largest sepsis-driven instrument sale in company history, with an initial order of seven T2Dx Instruments valued at over $450,000. The multi-year contract with Biomedica Poland includes the potential for nine additional instruments to be sold and deployed in Polish hospitals during H2 2023.
May 30, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
T2 Biosystems secures a significant sepsis-driven instrument sale, with an initial order of seven T2Dx Instruments valued at over $450,000, and potential for nine additional instruments to be sold in H2 2023.
The announcement of the second largest sepsis-driven instrument sale in T2 Biosystems' history is a positive development for the company. The initial order of seven T2Dx Instruments, valued at over $450,000, represents a significant revenue boost. Additionally, the potential for nine more instruments to be sold and deployed in H2 2023 indicates further growth opportunities. This news is likely to have a positive short-term impact on TTOO's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100